期刊文献+

齐拉西酮与氯氮平对首发精神分裂症患者生活质量影响

Comparative study on the influence of Ziprasidone and clozapine on quality of life in schizophrenic
下载PDF
导出
摘要 目的探讨齐拉西酮治疗对首发精神分裂症患者生活质量的影响。方法以齐拉西酮与氯氮平治疗精神分裂症各40例作对照研究,采用简明精神病评定量表(BPRS)不良反应量表(TESS)评定疗效及不良反应,WHOQ0L-BREF量表衡量患者的生活质量。结果最后一次评定,齐拉西酮组BPRS总分降至(15.62±4.37),与治疗前比较有显著性差异(P<0.01);氯氮平组BPRS总分降至(16.02±4.63),与治疗前比较有显著性差异(P<0.01)。两组间疗效无显著性差异(P>0.05)。氯氮平组毒副作用较齐拉西酮组多。经6个月治疗,齐拉西酮组的身心健康、心理健康、社会关系、环境因素的分值分别为(72.43±4.53),(94.87±10.55),(96.31±12.37),(95.43±10.12),氯氮平组的身心健康、心理健康、社会关系、环境因素的分值分别为(69.81±5.37)、(79.72±11.84)、(80.72±11.42、77).(74±10.56)。两组患者生活质量较治疗前均有显著改善(P<0.01),在心理健康、社会关系和环境因素等三方面,齐拉西酮优于氯氮平(P<0.01)。结论首发精神分裂症患者在提高患者生活质量方面,齐拉西酮优于氯氮平,有利于精神分裂症的远期康复。 Objective To investigate the influence on quality of life of Ziprasidone in schizophrenia Methods 40 schizophrenic patients were treated with ziprasidone as the controlled group. The Brief Psychiatric Rating Scale ( BPRS), while the adverse events were determined by the treatment emergent symptoms scale (TESS), WHOQOL-BREF instruments were used to evaluate the patients quality of life before and after drug administration. Results For the last assessment ,The scores of BPRS decrease to ( 15.62 ± 4. 37 ) in Ziprasidone group, was significantly lower than the beginning (P 〈0. 01 ) ; the scores of BPRS decrease to( 16.02 ± 4.63) in clozapine group, was significantly lower than the beginning ( P 〈 0. 01 ) ; Two groups showed similar effects, with no significance. The side effects were more in clozapine group than those in Ziprasidone group. 6 months after treatment, the scores of physical health, psychological health, social relationship, and environment in Ziprasidone group were ( 72.43 ± 4. 53 ), ( 94. 87 ±10. 55 ), ( 96. 31 ±12. 37 ), ( 95.43 ±10. 12 ) ; And the scores of physical halth, psychological health, social relationship, and environment in clozapine group were (69.81±5.37), (79.72± 11.84), (80.72 ±11.42), (77.74± 10.56). The scores of four domains in WHOQOL-BREF instruments had been improved significantly in two groups (P 〈0.01 ) In the mains of Psychological health, social Relation ship and Environment, Ziprasidone was superior to clozapine (P 〈 0.01 ). Conclusion Ziprasidone has more advantage than Clozapine to improve quality of life in schizophrenic and would be helpful to patients longterm rehabilitation.
出处 《中国实用医药》 2009年第25期20-22,共3页 China Practical Medicine
关键词 齐拉西酮 氯氮平 分裂症 生活质量 Ziprasidone Clozapine Schizophrenic Quality of life
  • 相关文献

参考文献9

  • 1中华医学会精神科分会.中国精神障碍分类与诊断标准第三版(CCMD-3).山东科学技术出版社,2001:87-89.
  • 2张作记.行为医学量表手册[J].中国行为医学科学,2001,:118-119.
  • 3world Health Orgnieation. WHOQOL Bref introduction. Administaration, scoring and generic version of the assessment, field trial version. Progamme on mental Henhh. WHO : Geneva, 1996 : 1-11.
  • 4Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone ,2 mg versus 10 rag,in the short-term management of agitated psychotic patients. J Clin Psychiatry ,2001,62 : 12-18.
  • 5Daniel DG, Potkin SG, Reeves KR,et al. Intramuscular(IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psyehopharmacology(Berl) ,2001,155 : 128-134.
  • 6Keck PE JR, Versiani M, Potkin A, et al. Ziprasidone in the treatment of acute bipolarmania: a three-week placebo-controlled, double- blind, randomized trial. Am J Psychiatry,2003,160:741-748.
  • 7Wilner KD, Anziano R J, Johnson AC, et al. The anxiolytie effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol,2002, 22:206-210.
  • 8Brook S, Lucey JV, Gunn KP. intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry,2000,61:933-941.
  • 9李乐华,赵靖平,许秀峰,蒙华庆,宁洁.国产齐拉西酮与氟哌啶醇注射液治疗精神分裂症急性激越症状的对照研究[J].中华精神科杂志,2006,39(4):216-219. 被引量:51

二级参考文献6

  • 1Miceli JJ,Anziano RJ,Robarge L,et al.The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.Br J Clin Pharmacol,2000,49 Suppl 1:65S-70S.
  • 2Lesem MD,Zajecka JM,Swift RH,et al.Intramuscular ziprasidone,2 mg versus 10 mg,in the short-term management of agitated psychotic patients.J Clin Psychiatry,2001,62:12-18.
  • 3Daniel DG,Potkin SG,Reeves KR,et al.Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis:a double-blind,randomized trial.Psychopharmacology (Berl),2001,155:128-134.
  • 4Brook S,Lucey JV,Gunn KP.Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis.J Clin Psychiatry,2000,61:933-941.
  • 5Keck PE Jr,Versiani M,Potkin S,et al.Ziprasidone in the treatment of acute bipolarmania:a three-week placebo-controlled,double-blind,randomized trial.Am J Psychiatry,2003,160:741-748.
  • 6Wilner KD,Anziano RJ,Johnson AC,et al.The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery.J Clin Psychopharmacol,2002,22:206-210.

共引文献1001

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部